The book begins with the basic science behind the medical applications of the knowledge: cardiovascular biology, pathways, and their relationship to cancer treatment and principles of chemotherapy and immunotherapy. The second section consists of an overview and classification of anti-cancer drugs and a look at their cardiotoxicity. The third section looks at cardiac imaging in the cancer patient, including cardiac ultrasound, Doppler imaging, nuclear imaging, magnetic resonance imaging, and computed tomography in the cancer patient. In section four, management of cardiac disease in the cancer patient is discussed, including cardiac rhythm disturbances and heart failure. Cardiac emergencies and interventions are described as is preoperative assessment of the cancer patient for non- cardiovascular surgery. The final section includes a range of topics such as the pericardium, cardiovascular effects of endocrine treatments, primary cardiac tumors and malignancies of the myocardium and pericardium. Cardiac monitoring during clinical trials and pulmonary concerns are also addressed, as are psychosocial, social, economic, and legal issues of the cancer patient with heart disease. Common terms and phrases: abnormalities activity acute addition agents anthracycline arrhythmias artery assessment associated benefit blood breast cancer cancer patients cardiac cardiotoxicity cardiovascular cause cell changes chemotherapy chest chronic Clin Oncol clinical common compared complications continuous coronary cumulative damage death decreased depression diagnosis dose doxorubicin drug dysfunction early echocardiography effects effusion elevated et al evaluation evidence factors FIGURE findings fraction function heart disease heart failure hypertension imaging imatinib important improve incidence increased indicated induced involvement irradiation lead less levels limited lung malignant mechanisms ment monitoring months mortality myocardial myocardial infarction normal occur oncology pericardial present pressure primary pulmonary radiation radiotherapy received reduced reported response risk seen severe significant stress suggests surgery surgical symptoms syndrome Table testing therapy tion tissue toxicity trastuzumab treated treatment trial tumors usually vascular ventricular